US5538503A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Programmable apparatus for reducing substance dependency in transdermal drug delivery
Assignee: MEDICAL IONOSONIC TECHNOLOGIES LLP
•
Filing: 1995-01-09
•
Granted: 1996-07-23
•
Expires: 2015-01-09
Abstract
Abstract An apparatus is described for the programmable iontophoretic or iontophoretic-ultrasonic (ionosonic) transdermal delivery of medication across the skin or other biological membrane. In one embodiment, the programmable apparatus controls the depth of penetration of a medicament into the skin. In another embodiment the programmed delivery of medicament is accompanied by an electrical stimulus for treating substance abuse. The apparatus can be adapted for large dermal area application or for a smaller area of application, depending on the choice of specific electrode employed. In a preferred embodiment the apparatus comprises a multichannel iontophoretic applicator electrode. Multiple piezoelectric elements are mounted on the iontophoretic electrode. The combination of ultrasonic vibration and iontophoresis improves the penetration of medicament in contact with the skin or mucous membrane underlying the electrode which can be programmably controlled by a CPU through the use of a EPROM. A wearable embodiment of an ionosonic or iontophoretic drug delivery system employing programmability may be used to produce response conditioning useful for the outpatient treatment of obesity, nicotine detoxification, and narcotic addiction detoxification.
Inventors
- 👤 Julian L. Henley
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 13:11
CPC Classifications
A; A61; A61N; A61N1/00; A61N1/02; A61N1/04; A61N1/0404; A61N1/0408; A61N1/0428; A61N1/0432; A61N1/044; A61M; A61M31/00; A61M31/002; A61M37/00; A61M37/0092; A61N1/18; A61N1/32; A61N1/325; A61M2037/0007; Y; Y10; Y10S; Y10S607/00; Y10S607/90
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
249 words
An apparatus for the transdermal delivery of medicament comprising a transdermal drug delivery portion and a stimulating portion, said transdermal drug delivery apparatus comprising: (a) a substantially planar, skin-contacting medicament carrying layer; and (b) an electrically conductive means in electrical communication with said medicament carrying layer; and (c) at least two electrodes including an iontophoresis electrode comprising a planar array of electrode channels, said iontophoresis electrode being substantially coplanar with said medicament containing layer and wherein said electrode channels are in electrical communication with both said medicament containing layer and said electrically conductive means; and (d) an ultrasonic element providing means operable for producing mechanical vibrations at ultrasonic frequencies in response to the application of a voltage thereto comprising at least one least one piezoelectric element in mechanical communication with said medicament containing layer which ultrasonic element produces ultrasonic compression waves in at least a portion of said skin-contacting medicament carrying layer; and (e) means for applying a voltage to said at least two electrodes; and (f) programmable means for controlling said means for applying a voltage to said at least two electrodes; said programmable means having stored therein a drug delivery portion for controlling the medicament dosage transdermally delivered and a stimulating portion for applying an electrical stimulus to said skin of a patient to produce a sensation upon each activation of said apparatus, said programmable means reducing said medicament dosage over time upon subsequent activations of said apparatus whereby the patients dependency on said medicament is reduced.
Claim 2
Independent Claim
249 words
An apparatus for the transdermal delivery of medicament comprising a transdermal drug delivery portion and a stimulating portion, said transdermal drug delivery apparatus comprising: (a) a substantially planar, skin-contacting medicament carrying layer; and (b) an electrically conductive means in electrical communication with said medicament carrying layer; and (c) at least two electrodes including an iontophoresis electrode comprising a planar array of electrode channels, said iontophoresis electrode being substantially coplanar with said medicament containing layer and wherein said electrode channels are in electrical communication with both said medicament containing layer and said electrically conductive means; and (d) an ultrasonic element providing means operable for producing mechanical vibrations at ultrasonic frequencies in response to the application of a voltage thereto comprising at least one least one piezoelectric element in mechanical communication with said medicament containing layer which ultrasonic element produces ultrasonic compression waves in at least a portion of said skin-contacting medicament carrying layer; and (e) means for applying a voltage to said at least two electrodes; and (f) programmable means for controlling said means for applying a voltage to said at least two electrodes; said programmable means having stored therein a drug delivery portion for controlling the medicament dosage transdermally delivered and a stimulating portion for applying an electrical stimulus to said skin of a patient to produce a sensation upon each activation of said apparatus, said programmable means reducing said medicament dosage over time upon subsequent activations of said apparatus whereby the patients dependency on said medicament is reduced.
Claim 3
Dependent Claim
26 words
The apparatus according to claim 1 wherein the electrically conductive means comprises a metallic film selected from the group consisting of copper, platinum, gold or silver.
Claim 4
Dependent Claim
17 words
The apparatus according to claim 1 wherein the medicament carrying layer comprises an open-celled, absorbent porous material.
Claim 5
Dependent Claim
26 words
The apparatus according to claim 3 wherein the open-celled, absorbent porous material is selected from the group consisting of polyethylene, paper, cotton, silicone, polytetrafluoroethylene and ceramic.
Claim 6
Independent Claim
151 words
An apparatus for the transdermal delivery of medicament comprising a transdermal drug delivery portion and a stimulating portion, said transdermal drug delivery apparatus comprising: (a) a skin-contacting medicament portion; and (b) at least two electrodes including an electrode in electrical contact with said medicament portion for delivering drug to the patient; and (c) means for applying a voltage to said at least two electrodes; and (d) programmable means for controlling said means for applying a voltage to said at least two electrodes; said programmable means having stored therein a drug delivery portion for controlling the medicament dosage transdermally delivered to the patient and a stimulating portion for applying an electrical stimulus to said skin of a patient to produce a sensation upon each activation of said apparatus, said programmable means reducing said medicament dosage over time upon subsequent activations of said apparatus whereby the patient's dependency on said medicament is reduced.
Claim 7
Independent Claim
151 words
An apparatus for the transdermal delivery of medicament comprising a transdermal drug delivery portion and a stimulating portion, said transdermal drug delivery apparatus comprising: (a) a skin-contacting medicament portion; and (b) at least two electrodes including an electrode in electrical contact with said medicament portion for delivering drug to the patient; and (c) means for applying a voltage to said at least two electrodes; and (d) programmable means for controlling said means for applying a voltage to said at least two electrodes; said programmable means having stored therein a drug delivery portion for controlling the medicament dosage transdermally delivered to the patient and a stimulating portion for applying an electrical stimulus to said skin of a patient to produce a sensation upon each activation of said apparatus, said programmable means reducing said medicament dosage over time upon subsequent activations of said apparatus whereby the patient's dependency on said medicament is reduced.
References Cited (Backward Citations)
US4211222A
Cited
SU654254A2
Cited
SU931191A1
Cited
SU1003853A1
Cited
US4708716A
Cited
US4767402A
Cited
US5002527A
Cited
JPH01309093A
Cited
US4950229A
Cited
JPH03170172A
Cited
US5115805A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-07-23 | 2000-01-22 | 2000-07-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-07-23 | 2004-01-22 | 2004-07-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-07-23 | 2008-01-22 | 2008-07-23 | $7700.00 | Window Closed / Lapsed |